Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Lavdosis Tenecteplase til behandling af akut iskæmisk apopleksi hos aldrende patienter (DATE-AGING)

1. november 2026 opdateret af: Zhenhua Zhou, Southwest Hospital, China

Effektivitet og sikkerhed af lavdosis tenecteplase til behandling af akut iskæmisk apopleksi hos aldrende patienter: En prospektiv, multicenter, randomiseret kontrolleret undersøgelse

The DATE-AGING study is a prospective, multicenter, randomized controlled trial investigating low-dose tenecteplase in elderly patients with acute ischemic stroke. Its primary objective is to evaluate the safety and efficacy of low-dose tenecteplase in elderly patients within 4.5 hours of acute ischemic stroke onset.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

806

Fase

  • Fase 4

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Anshan, Kina
        • Anshan Changda Hospital
      • Anyang, Kina
        • Anyang People's Hospital
      • Anyang, Kina
        • Huaxian People's Hospital of Henan
      • Baoshan, Kina
        • Baoshan People's Hospital
      • Bijie, Kina
        • People's Hospital of Zhijin County
      • Chongqing, Kina
        • Chongqing University Three Gorges Hospital
      • Chongqing, Kina
        • Chongqing University Jiangjin Hospital
      • Chongqing, Kina
        • Bishan Hospital
      • Chongqing, Kina
        • Chongqing Emergency Medical Center
      • Chongqing, Kina
        • Chongqing University Fuling Hospital
      • Chongqing, Kina
        • Dianjiang People's Hospital OF Chongqing
      • Chongqing, Kina
        • People's Hospital Of Xiushan County
      • Chongqing, Kina
        • The People's Hospital of Dazu Chongqing
      • Chongqing, Kina
        • The People's Hospital of HeChuan, Chongqing
      • Chongqing, Kina
        • The People's Hospital of Rongchang Chongqing
      • Chongqing, Kina
        • The People's Hospital of Tongnan District Chongqing City
      • Chongqing, Kina
        • The Seventh People's Hospital of Chongqing
      • Chongqing, Kina
        • Tongliang Hospital
      • Chongqing, Kina
        • Yunyang County People's Hospital
      • Dali, Kina
        • Dali Bai Autonomous Prefecture People's Hospital
      • Dazhou, Kina
        • Dazhou Central Hospital
      • Deyang, Kina
        • The People's Hospital of Zhongjiang
      • Guang’an, Kina
        • Guang an People's Hospital
      • Guiyang, Kina
        • Guizhou Provincial People's Hospital
      • Guiyang, Kina
        • The Second People's Hospital of Guiyang(Guiyang Jinyang Hospital)
      • Ha’erbin, Kina
        • The First Affiliated Hospital of Harbin Medical University
      • Hebi, Kina
        • Xunxian People's Hospital
      • Heyuan, Kina
        • Heyuan People's Hospital
      • Huanggang, Kina
        • Qichun People's Hosiptal
      • Jianyang, Kina
        • The People's Hospital Of Jianyang City
      • Laixi, Kina
        • Laixi People's Hospital
      • Leshan, Kina
        • People's Hospital of Leshan
      • Leshan, Kina
        • Leshan Geriatric Specialized Hospital
      • Luoyang, Kina
        • Luoyang Mengjin People's Hospital
      • Nanchong, Kina
        • Nanbu People's Hospital
      • Pujiang, Kina
        • Puyang People's Hospital
      • Pujiang, Kina
        • The People's Hospital of Nan Le Xian
      • Shangqiu, Kina
        • People's Hospital of Ningling County
      • Shangqiu, Kina
        • The First People's Hospital of Shangqiu
      • Shaoyang, Kina
        • The First People ' S Hospital of Shao Yang
      • Shijiazhuang, Kina
        • The People's Hospital of Gaocheng
      • Wuhan, Kina
        • Wuhan Puren Hospital
      • Xiangyang, Kina
        • Xiangyang NO.1 People's Hospital
      • Yibin, Kina
        • The second people's hospital of Yibin
      • Zhumadian, Kina
        • Zhumadian Central Hospital
      • Zhuzhou, Kina
        • Zhuzhou Central Hospital
      • Zigong, Kina
        • Zigong Third People's Hospital
      • Ziyang, Kina
        • Ziyang Central Hospital
    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, Kina, 400038
        • Southwest Hospital, Chongqing, China
    • Heilongjiang
      • Harbin, Heilongjiang, Kina, 150200
        • Wuchang People's Hospital
    • Henan
      • Zhoukou, Henan, Kina, 466300
        • Shenqiu County People's Hospital

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

70 år og ældre (Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Age ≥ 70 years;
  2. Diagnosis of ischaemic stroke with a measurable neurological deficit on National Institutes of Health Stroke Scale (NIHSS) (1≤ NIHSS ≤25); if NIHSS <4, patients have to be with at least a measurable deficit on motor power (upper or lower limbs ≥1);
  3. Stroke symptoms should have been present for at least 30 minutes (min) without significant improvement prior to randomisation;
  4. Thrombolytic therapy can be initiated within 4.5 Hour(s) (h) of Acute ischaemic stroke (AIS) onset;
  5. Patients with premorbid modified Rankin Scale (mRS) 0 or 1;
  6. Informed consent from the patient or surrogate.

Exclusion Criteria:

  1. Imaging demonstrates multi-lobar infarction (hypodensity >1/3 cerebral hemisphere);

  2. Acute bleeding diathesis or allergy to tenecteplase, including but not limited to

    • Known genetic predisposition to bleeding or significant bleeding disorder at present or within the past 6 Month(s) (m)
    • Administration of heparin within the previous 48 h and activated partial thromboplastin time (aPTT) exceeding the upper limit of normal for laboratory measurement
    • Current use of vitamin K based oral anticoagulants (e.g. warfarin) and a prolonged prothrombin time (International normalised Ratio (INR) > 1.7 or Prothrombin time (PT)>15 seconds (s)) or current use of novel oral anticoagulants (i.e. dabigitran, rivaroxiban, or apixiban) with prolongation of activated partial thromboplastin time (aPTT) and/or PT above the upper limit of the local laboratory reference range
    • Platelet count of below 100×10^9/ L
    • Any history of central nervous system damage (i.e. neoplasm, aneurysm, intracranial or spinal surgery)
    • Recent traumatic external heart massage or recent puncture of a non-compressive blood-vessel (e.g. subclavian or jugular vein puncture) , within the past 10 days
    • Known history of suspected intracranial haemorrhage or suspected subarachnoid haemorrhage from aneurysm
    • Neoplasm with increased haemorrhagic risk
    • Documented ulcerative gastrointestinal disease during the last 3 months, oesophageal varices, arterial aneurysm, or arterial/venous malformations
    • History of significant trauma or major surgery within the past 3 months.
    • Any known disorder associated with a significant increased risk of bleeding
  3. Intracranial hemorrhage (including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural/extradural hematoma, etc.);

  4. Blood glucose <2.8 mmol/L or >22.22 mmol/L;

  5. After active antihypertensive treatment, hypertension is still not under control: systolic blood pressure ≥180 mmHg, or diastolic blood pressure ≥100 mmHg;

  6. Seizure at stroke onset;

  7. Concurrent malignancy or severe systemic disease with an anticipated survival of less than 90 days;

  8. Participation in other clinical trials within 3 months prior to screening;

  9. Unsuitability or participation in this study as judged by the Investigator may result in subjects being exposed to greater risk.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Enkelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Low-Dose Tenecteplase

0.175mg/kg tenecteplase

Subjects will be randomized to low-dose group or standard-dose group in a 1:1 ratio. Patients in the low-dose group received tenecteplase (0.175 mg/kg) for intravenous thrombolysis. The upper dose limit is set to 17.5 mg/patient.

Aktiv komparator: Standard-Dose Tenecteplase

0.25mg/kg tenecteplase

Subjects will be randomized to low-dose group or standard-dose group in a 1:1 ratio. Patients in the standard-dose group received tenecteplase (0.25 mg/kg) for intravenous thrombolysis. The upper dose limit is set to 25 mg/patient.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Percentage of Participants With Modified Rankin Scale (mRS) Score of 0 or 1
Tidsramme: At Day 90±7 days

Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death).

At Day 90±7 days

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Percentage of participants with major neurological improvement (National Institutes of Health Stroke Scale (NIHSS) score of 0 or improvement of at least 4 points compared with baseline)
Tidsramme: At 24 hours

National Institutes of Health Stroke Scale (NIHSS) is a 11-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 6 grades with 0 as normal, and there is an allowance for untestable items.Total NIHSS score (0-42) = sum of 11 individual item scores, higher total scores meaning more severe deficits.

At 24 hours
Percentage of Participants With Modified Rankin Scale (mRS) Score of 0-2
Tidsramme: At Day 90±7 days

Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death).

At Day 90±7 days
Distribution of Modified Rankin Scale (mRS)
Tidsramme: At Day 90±7 days

Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death).

At Day 90±7 days
Percentage of Participants With Barthel Index Score ≥95
Tidsramme: up to 90 days

The Barthel Index is an ordinal scale used to measure performance in activities of daily living (ADL). The Barthel Index consists of 10 items. The total score of the Barthel Index ranges from 0 to 100, and higher scores indicate better outcome.

up to 90 days
EQ-5D-5L score
Tidsramme: At Day 90±7 days

Health-related quality of life (the score on the EuroQol Group 5-Dimension 5-Level [EQ-5D-5L] questionnaire, range, -0.39 to 1, with higher scores indicating better quality of life)

At Day 90±7 days
Percentage of Participants With Symptomatic Intracerebral Haemorrhage (sICH)
Tidsramme: up to 36 hours

sICH via criteria adapted from the European Cooperative Acute Stroke Study (ECASS III), defined as any apparent extravascular blood in the brain or within the cranium that is associated with clinical deterioration defined by an NIHSS score increase of four points or more from baseline.

up to 36 hours
All-cause mortality
Tidsramme: up to 90 days

All-cause mortality at 90 days

up to 90 days
Percentage of Participants With Modified Rankin Scale (mRS) Score of 5 or 6
Tidsramme: At Day 90±7 days

Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death).

At Day 90±7 days

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

19. december 2025

Primær færdiggørelse (Faktiske)

1. november 2026

Studieafslutning (Faktiske)

1. november 2026

Datoer for studieregistrering

Først indsendt

21. november 2025

Først indsendt, der opfyldte QC-kriterier

7. december 2025

Først opslået (Faktiske)

19. december 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

3. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

1. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 2025IITDA10

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • SAP
  • CSR

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .